Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B

Trial Profile

Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Emtricitabine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Feb 2017 Status changed from recruiting to discontinued.
    • 26 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 4 Jan 2018.
    • 05 Jan 2017 Planned End Date changed from 1 Jan 2019 to 1 Jan 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top